Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 17/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 16/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238877 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7216415 | 0.86 | EGFR (0.84) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220753 | 0.85 | EGFR (0.84) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220739 | 0.84 | EGFR (0.83) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL2993868 | 0.83 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220678 | 0.81 | EGFR (0.75) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220061 | 0.81 | EGFR (0.79) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7220144 | 0.81 | EGFR (1.00) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7221044 | 0.80 | EGFR (0.91) | EGFRERBB2ERBB4MEN1KMT2A | |
| SCHEMBL7243805 | 0.79 | EGFR (0.66) | EGFRERBB2ERBB4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | claimed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4011376-B1 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4477222-A2 | CRYSTALLINE 4-(5-CHLORO-2-ISOPROPYLAMINOPYRIDIN-4-YL)-1H-PYRROLE-2-CARBOXYLIC ACID [1-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMIDE HYDROCHLORIDE SALT | Biomed Valley Discoveries, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | disclosed |
| US-20220288207-A1 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11439669-B2 | C. novyi for the treatment of solid tumors in humans | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| WO-2022165185-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022159687-A1 | PHENOTYPIC ASSAY TO IDENTIFY PROTEIN DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11260132-B2 | Engineered liposomes as cancer-targeted therapeutics | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885ERBB2 452/4885ERBB4 1808/4885 |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885ERBB2 452/4885ERBB4 1808/4885 |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | MKI67, HCCS, NCF1 | EGFR 1667/4885ERBB2 1977/4885ERBB4 2380/4885 |
| US-20220288207-A1 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | UBE3C, PSMC1, UBE3A | EGFR 2133/4885ERBB2 1909/4885ERBB4 3020/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885ERBB2 452/4885ERBB4 1808/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | EGFR 3015/4885ERBB2 2467/4885ERBB4 3045/4885 |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ROS1, ALK, PTK2 | EGFR 5/4885ERBB2 6/4885ERBB4 9/4885 |
| US-11439669-B2 | C. novyi for the treatment of solid tumors in humans | HCCS, MKI67, PBK | EGFR 1748/4885ERBB2 1686/4885ERBB4 2328/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885ERBB2 452/4885ERBB4 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.